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Objectives. To provide a comprehensive appraisal of the evidence from secondary research on cardiac regenerative therapy. Study
Design and Setting. Overview of systematic reviews of controlled clinical trials concerning stem cell administration or mobilization
in patients with cardiovascular disease.Results. After a systematic database search, we short-listed 41 reviews (660 patients). Twenty-
two (54%) reviews focused on acutemyocardial infarction (AMI), 19 (46%) on chronic ischemic heart disease (IHD) or heart failure
(HF), 29 (71%) on bone marrow-derived stem-cells (BMSC), and 36 (88%) to randomized trials only. Substantial variability among
reviews was found for validity (AMSTAR score: median 9 [minimum 3]; 1st quartile 9; 3rd quartile 10; maximum 11), effect estimates
(change in ejection fraction from baseline to follow-up: 3.47% [0.02%; 2.90%; 4.22%; 6.11%]), and citations (Web of Science yearly
citations: 4.1 [0; 2.2; 6.5; 68.9]). No significant association was found between these three features. However, reviews focusing on
BMSC therapy had higher validity scores (𝑃 = 0.008) and showed more pronounced effect estimates (𝑃 = 0.002). Higher citations
were associated with journal impact factor (𝑃 = 0.007), corresponding author from North America/Europe (𝑃 = 0.022), and
inclusion of nonrandomized trials (𝑃 = 0.046). Conclusions. Substantial heterogeneity is apparent among these reviews in terms of
quality and effect estimates.
1. Introduction
Heart failure (HF) represents a common final pathway for
many patients with ischemic heart disease (IHD) or other
chronic cardiac conditions [1], yet, the paradigm that the
heart is a terminally differentiated organwithout regenerative
capacity has been challenged several times [2, 3]. In addition,
we may also envision means to implant by various routes
autologous or heterologous stem cells which may eventually
regenerate the heart either directly, that is, by differentiating
into cardiomyocytes, or indirectly, that is, by exerting local
humoral effects which activate endogenous cardiac regenera-
tive potential through paracrine enhancement, angiogenic, or
anti-inflammatory actions [4–8]. Accordingly, several clinical
trials, mostly phases 2 and 3, have been conducted on cardiac
regenerative therapy [9, 10]. However, uncertainty persists
given the limitations of existing studies and the difficulty in
standardizing such regenerative therapy protocols [11].
Systematic reviews are commonly used for evidence
synthesis, pooling original studies (i.e., primary research),
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in order to increase precision, test for homogeneity and
consistency, and explore the impact of moderators [12].
Accordingly, systematic reviews are often defined as sec-
ondary research.Another layer of evidence synthesis has been
recently advocated, based on the search, analysis, and inter-
pretation of systematic reviews. This additional level of
evidence synthesis is called tertiary research, and typical
tools consist of umbrella reviews (i.e., overviews of reviews)
andmetaepidemiologic studies [13]. Umbrella reviews consist
indeed of explicit and systematic overviews of previously
published systematic reviews and meta-analyses focusing at
large on a clinical topic. They represent a relatively novel and
remarkably efficient tool to synthesize the evidence base on
a specific clinical topic and highlight key discrepancies. Prior
efforts at reconciling discrepancies betweenmeta-analyses on
the same topic have occurred [14], but to date there is no
comprehensive overview of reviews on cardiac regenerative
therapy. Accordingly, we aimed to undertake such a scholarly
endeavor, with three specific goals: (a) appraising review
quality and its predictors; (b) appraising consistency in effect
estimates and their predictors; and (c) quantifying scholarly
citations and their predictors.
2. Materials and Methods
2.1. Design. This review was performed and is reported in
keeping with the Preferred Items for Systematic Reviews and
Meta-Analyses (PRISMA) recommendations, but without a
specific a priori protocol [15]. All reviewing activities were
performed by two independent and experienced reviewers,
with divergences resolved after consensus.
2.2. Search and Selection. The search for systematic reviews
and meta-analyses on cardiac regenerative medicine was
based on a dedicated search of The Cochrane Library and
on an explicit query in MEDLINE/PubMed, last updated on
July 26, 2014, performed with the Clinical Queries tool using
the following as string: (cardiac OR coronary OR heart OR
myocardi∗) AND ((growth AND factor∗) OR (regeneration
OR regenerative OR stem OR cell∗) AND therapy).
After screening at the title and abstract level, the full text
of potentially eligible reviewswas analyzed leading to the final
inclusion only of systematic reviews of clinical trials includ-
ing statistical pooling of quantitative estimates (i.e., meta-
analysis) of prognostic, cardiac function, or symptomatic
data stemming from clinical trials on cardiac regenerative
therapy, including stem cell administration or mobilization
with growth factors, stimulating factors, or gene therapy.
Specifically, fatal and nonfatal clinical events (including
rehospitalizations) were considered as prognostic endpoints,
parameters of left ventricular function, dimension, or via-
bility, as well as cardiopulmonary function parameters, were
considered as cardiac remodeling and/or cardiac function
parameters, and functional class or prevalence of specific
symptoms were considered as symptomatic endpoints. Refer-
ence lists of included studies were also screened for additional
suitable articles. In addition, we excluded studies published in
non-English language.
2.3. Abstraction, Quality Appraisal, Effect Estimate, and Cita-
tion Count. We extracted a comprehensive set of key study,
patient, procedural, outcome, and validity features from
the included studies. We explicitly appraised review quality
with A Measurement Tool to Assess Systematic Reviews
(AMSTAR) tool, which is an externally validated tool for
the evaluation of the internal validity of a systematic review
[16]. Effect estimates from included reviews were extracted as
point estimates and 95% confidence intervals, with standard
errors back-computed according to normal approximation.
Finally, we obtained citation counts and computed yearly cita-
tions for each shortlisted review published before November
15, 2013, from Web of Science, Scopus, and Google Scholar.
Specifically, yearly citations were computed as total citations
divided by the time elapsed between publication and cita-
tional database analysis. Citation counts were last updated on
November 15, 2014.
2.4. Analysis. Continuous variables are reported as median
(minimum; 1st quartile; 3rd quartile; maximum). Categor-
ical variables are reported as count (percentage). Bivariate
analyses were based on Student’s 𝑡-test, ANOVA, linear
regression, or Fisher exact test. Multifactorial regression
(i.e., regression with multiple independent variables but a
single dependent variable) was based on linear or logistic
regression with backward stepwise selection (𝑃 for removal
0.10). As an additional analysis, we explored the association
between moderators and outcomes of interest with random
effects metaregression, using as weights the within-review
standard errors. Heterogeneity in effect estimates was also
explored with Cochran 𝑄 test and 𝐼2. To take into account
the skewness in yearly citation counts, these were used for
regression analysis after natural logarithm transformation.
Statistical significancewas set at the two-tailed 0.05 level, with
𝑃 values unadjusted for multiplicity reported throughout.
Computations were performed with Stata 13 (StataCorp,
College Station, TX, USA).
3. Results and Discussion
From a total of 709 citations, 41 were finally included in the
main analysis for validity and effect estimates and 36 in the
citation analysis (online references; Table 1; see Table 1S, Table
2S, and Table 3S in Supplementary Material available online
at http://dx.doi.org/10.1155/2015/613782; Figure 1).Thesewere
published between 2006 and 2014 and included a median
of 10 studies (minimum 2; 1st quartile 7; 3rd quartile 18;
maximum50) and 660 patients (179; 412; 985; 2,625) (Table 1).
Most (36 [88%]) reviews included only randomized clinical
trials (RCT) but 6 (12%) did include both RCTs and non-
RCTs, typically using for the latter type of study unadjusted
effect estimates, while 22 (54%) focused on acute myocardial
infarction (AMI), 19 (46%) focused on chronic ischemic heart
disease (IHD) or heart failure (HF), and 29 (71%) limited
their scope to bone marrow-derived stem cells (BMSC).
Review validity was typically high (average of 9 out of
11) but remarkably variable (3; 9; 10; 11). Out of all the
reviews, two (5%) reviews suggested a beneficial effect on
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Table 1: Key features of the 41 included reviews.
Feature Median or count(%) Minimum 1st quartile 3rd quartile Maximum
Year of publication 2011 2006 2009 2013 2014
Authors 6 2 4 8 26
North American/European corresponding author 21 — — — —
Studies included 10 2 7 18 50
Patients included 660 179 412 985 2,625
Randomized trials only 36 — — — —
Type of setting
Acute myocardial infarction 22 (54%) — — — —
Chronic ischemic heart disease or heart failure 19 (46%) — — — —
Type of therapy
Any stem cell 6 (15%) — — — —
Bone marrow-derived stem cell 29 (71%) — — — —
Granulocyte-colony stimulating factor 5 (12%) — — — —
Other 1 (2%) — — — —
Patient-level meta-analysis 2 (5%) — — — —
Random effects 36 (88%)
Small study effect testing 34 (83%)
Subgroup analysis 38 (93%) — — — —
Metaregression 8 (20%) — — — —
Conflict of interests 2 (5%) — — — —
Funding 27 (66%) — — — —
AMeasurement Tool to Assess Systematic Reviews (AMSTAR) score 9 3 9 10 11
Favorable findings on prognosis 12 (29%) — — — —
Favorable findings on symptoms 2 (5%) — — — —
Favorable findings on cardiac function parameters or signs 32 (78%) — — — —
Change in left ventricular ejection fraction 3.47% 0.02% 2.90% 4.22% 6.11%
Yearly Web of Science citations 4.1 0 2.2 6.5 68.9
Yearly Scopus citations 5.1 0 2.5 7.4 81.8
Yearly Google Scholar citations 7.3 0 3.2 11.3 105.2
symptoms, prognostic benefits were reported by 12 (29%)
reviews, and 32 (78%) reviews reported on cardiac function
parameters or signs of cardiac disease. Quantitative effect
estimates were also variable (median change in LVEF = 3.47%
[0.02%; 2.90%; 4.22%; 6.11%]; 𝑃 for heterogeneity ranging
from <0.001 to 0.880, 𝐼2 ranging from 96% to 0%), having
no significant association with review validity or year of
publication (Figures 2 and 3), despite an improvement in
precision over the years (linear regression of the standard
error of the change in LVEF versus year: coefficient = −0.10,
standard error = 0.04, 𝑃 = 0.019). Yearly scholarly citations
were on average 4.1 (0; 2.2; 6.5; 68.9) inWeb of Science, 5.1 (0;
2.5; 7.4; 81.8) in Scopus, and 7.3 (0; 3.2; 11.3; 105.2) in Google
Scholar and were also not apparently associated with review
quality or quantitative effect estimates.
A more formal analysis of moderators or features poten-
tially explaining the wide variability in AMSTAR scores,
change in LVEF, and yearly citations was conducted, apprais-
ing at bivariate analysis an exhausting list of variables: year of
publication, journal impact factor, journal subject, number
709 citations initially retrieved
663 citations initially retrieved
46 citations shortlisted
5 excluded because they are not in
providing a quantitative synthesis
41 included in the main analysis
5 excluded because they are published 
after November 15, 2013
36 included in the citation analysis
English or are not
Figure 1: Review profile.
of authors, country of corresponding author, specialty of cor-
responding author, review design, studies included, patients
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Figure 2: Forest plot for improvement in cardiac function (change in left ventricular ejection fraction). AMI = acute myocardial infarction;
AMSTAR = A Measurement Tool to Assess Systematic Reviews; BMSC = bone marrow-derived stem cell; CHD = congestive heart failure;
G-CSF = granulocyte-colony stimulating factor; IHD = ischemic heart disease; LLCI = lower limit of the 95% confidence interval; PE = point
estimate; RCT = randomized clinical trial; SC = stem cell; ULCI = upper limit of the 95% confidence interval.
Table 2: Bivariate and multivariable analysis for review quality, effect estimates, and scholarly citations.
Dependent variable Independent variable(s) Bivariate analysis
∗ Multivariable analysis†
Coefficient Standard error 𝑃 Coefficient Standard error 𝑃
AMSTAR score Year of publication 0.27 0.11 0.022 0.21 0.11 0.052
BMSC therapy 1.58 0.57 0.009 1.36 0.56 0.021
Change in LVEF (%) BMSC therapy 1.41 0.42 0.002 — — —
Yearly Web of Science
citations
Journal impact factor 0.85 0.20 <0.001 0.56 0.20 0.007
Authors 0.10 0.04 0.034 — — —
Corresponding author from North
America or Europe 1.32 0.33 <0.001 0.77 0.32 0.022
Studies included 0.04 0.02 0.037 — — —
Patients included (×100 people) 0.07 0.03 0.030 — — —
RCTs only −1.35 0.56 0.023 −0.90 0.43 0.046
∗Only independent variables significantly (𝑃 < 0.05) associated with the dependent variable of interest are reported, but all the following variables were tested:
year of publication, authors, North American/European corresponding author, studies included, patients included, RCTs only, type of setting, BMSC therapy,
patient-level design, random effects analysis, small study effect testing, subgroup analysis, metaregression, conflict of interests, and funding; †a multivariable
linear regression model with backward stepwise selection (𝑃 for exit 0.10) was used, including in the model all variables significantly (𝑃 < 0.05) associated
with the dependent variable at bivariate analysis; A Measurement Tool to Assess Systematic Reviews (AMSTAR) score; BMSC = bone marrow-derived stem
cell; LVEF = left ventricular ejection fraction; RCT = randomized clinical trial.
included, type of included studies, clinical setting, type
of therapy, impact on prognosis, cardiac function parame-
ters/signs or symptoms, funding, conflict of interests, random
effects for pooling, subgroup analyses, and metaregression
(Table 2). Despite this comprehensive set of analyses, only
focus on BMSC therapy was found to be significantly asso-
ciated with AMSTAR scores (𝑃 = 0.021) and change in LVEF
(𝑃 = 0.002). Conversely, scholarly citations were significantly
and positively predicted by journal impact factor (0.007) and
corresponding author from North America/Europe (0.022).
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Figure 3: Association between review quality (measured with A Measurement Tool to Assess Systematic Reviews (AMSTAR) score), effect
estimates for improvement in cardiac function (change in left ventricular ejection fraction (LVEF)), and yearly scholarly citations: (a)
AMSTAR score and change in LVEF; (b) AMSTAR score and yearly citations in Web of Science (WOS); (c) change in LVEF and yearly
citations in WOS; (d) yearly citations in WOS and yearly citations in Scopus (dots) or Google Scholar (circles).
Finally, and rather surprisingly, reviews including RCTs as
well as nonrandomized trials received more yearly citations
than meta-analyses limited to RTCs only (𝑃 = 0.046). Bivari-
ate and multivariable regression analyses were confirmed at
random effects meta-regression, with very similar results in
terms of statistical magnitude and direction.
The field of cardiac regenerative therapy has seen signifi-
cant changes since the paradigm that the heart is a terminally
differentiated organ was challenged. The amount of human
and economic resources invested to date in this field has been
extremely large, yet conclusive trials in cardiac regenerative
therapy have not been completed, and the therapy has not
affected clinical practice in any measurable way [1, 3, 17, 18].
There are several explanations for these setbacks, includ-
ing our limited understanding of physiology and pathophys-
iology of cardiomyocytes, as well as stem cells, difficulties
in standardizing protocols for cell harvesting and expansion,
complexity in culture standardization, issues in identifying
the correct patient subsets who aremost likely to benefit from
cardiac regenerative therapy, and difficulties in conducting
high quality clinical trials [19–22]. Indeed, most studies to
date have been preclinical ones, either focused on activity
and efficacy (phase 2) or focused on initial evidence of
effectiveness (phase 3), with single-center design and obvious
limitations in internal and external validity.
Despite this, or possibly exactly for this reason, cardiac
regenerative therapy has been the focus of intense research
synthesis efforts, with the publication of many systematic
reviews and meta-analyses including basic research as well
as human clinical studies. Nonetheless, the heterogeneity
between primary studies has beenmirrored by heterogeneous
results and conclusions among available meta-analyses, fur-
ther complicating decision making on this topic. Overviews
of reviews and umbrella reviews, together withmetaepidemi-
ologic studies, are now commonly used to summarize and
appraise the evidence base on specific clinical topics, while
maintaining the ability to focus on the single piece of evidence
being lumped together with similar ones [12, 23].
Our present umbrella review provides indeed a concise
yet comprehensive appraisal of 41 systematic reviews of clin-
ical trials on cardiac regenerative therapy, pooling together
dozens of studies and thousands of patients (not discounting
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duplicates). We found indeed that the evidence base on
G-CSF and Ad5FGF-4 suggests no net effect on clinical
events, cardiac remodeling, or symptoms in patients with
AMI, chronic IHD, or HF. Most reviews that have focused
on BMSC administration, instead, suggest some net benefit
on cardiac remodeling, even if this is not large in absolute
terms and might thus be not clinically relevant. In addition,
some studies reported also a favorable effect on prognosis
and symptoms, but these estimates may be undermined by
reporting bias or other confounding factors. We have also
highlighted the huge variability in review quality, effect esti-
mates, and scholarly citations. In addition, we have explored
potential moderators of these features, emphasizing the fact
that type of therapy, journal impact factor, geographic area of
corresponding authors from North America or Europe, and
focus on non-RCTS are the only meaningful predictors for
one or more of such features.
Indeed, a looming presence in this scholarly field is the
concept of discrepancies, biases, and unreliable data, which
may apply to some ormany of the potentially eligible primary
studies. For instance, it is troubling that de Jong et al. have
not shown any benefit of BMSC on MRI-derived cardiac
function parameters at odds with other studies using mainly
echocardiographic data, which are considered much more
prone to observer bias. Interpretation and decision making
become even more complicated in light of the discrepancies
in autologous bone marrow stem cell trials and enhancement
of ejection fraction (DAMASCENE) analysis by Nowbar and
colleagues, which disclosed over 600 discrepancies among
133 study reports stemming from 49 clinical trials on BMSC,
concluding that the more the discrepancies, the greater the
apparent effect of BMSC on LVEF [24]. All these lessons
learned since the earliest clinical trials, mostly based on
extracardiac cell sources, should hopefully pave the way for
more accurate and critical design and interpretation of the
latest trials for cardiac regenerative medicine, exploiting
cardiac resident populations of progenitor cells.
These findings suggest that researchers, clinicians, fun-
ders, and patients should exert great caution in interpreting
results of studies on cardiac regenerative therapy, to avoid an
overoptimistic interpretation, as well as undue funding of less
than promising research avenues. In addition, our results call
for greater attention to details and internal validity and for a
more cautious stance to any report of overwhelming clinical,
remodeling, or symptomatic benefit of cardiac regenerative
therapy [25]. The role of funding agencies (either private or
public) will continue to remain crucial, with the need for
careful assessment of the true merits of future preclinical and
clinical research protocols, in order to minimize the risk of
biased findings and hopefully bridge the gap between poten-
tial and actual benefits for patients. Having also early phase
studies designed as rigorous placebo- or sham-controlled
RCTs might be beneficial, in order to minimize the risk of
bias. However, providing more formal recommendations is
beyond the scope of the umbrella review design of the present
work.
Despite our extensive effort, this overview of reviews has
many limitations, and it should be interpreted with caution,
as any form of nonprimary research. In particular, we limited
our search toMEDLINE/PubMed and articles in English, and
our work carries the risk, as any similar effort, of multiplicity
and ecological fallacy [26, 27]. Conversely, the choice of
using the Fisher exact test for bivariate analysis of categorical
variables may have led to reduced statistical precision and
power. However, we chose this analytical strategy in order
to minimize the risk of type I error and multiplicity. Finally,
while the reader might be tempted by the idea of performing
a meta-analysis of the included meta-analyses, such analysis
would be fraught by a major tautology issue, with some
studies providing effect estimates larger than the real ones
because they had been included in several reviews. Indeed,
despite differences in the search and ultimate selection of
studies, the core set of included trials was common to most
meta-analyses (Figure 1S). Accordingly, no such analysis was
performed.
4. Conclusions
Substantial heterogeneity is apparent among reviews on
cardiac regenerative therapy completed to date in terms of
quality and effect estimates, with no improvement in such
key dimensions over time and a disturbing lack of or negative
association between review quality and subsequent scholarly
impact.
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